November 18, 2024

SPT Labtech brings the power of miniaturization to more genomics researchers with mosquito® Gen3

SPT Labtech brings the power of miniaturization to more genomics researchers with mosquito® Gen3

This new instrument delivers automated true positive displacement technology in an exceptionally compact footprint

Cambridge, UK SPT Labtech, a global leader in the design, development and manufacture of automated instrumentation and consumables for life science applications, has expanded its nanoliter liquid handling portfolio with the launch of mosquito Gen3. As the most compact and accessible model of the mosquito range, this new instrument brings next-generation sequencing (NGS) cost savings to more laboratories by lowering the barrier to advanced miniaturization technology.

mosquito Gen3 delivers accurate and precise multi-channel pipetting from 500 nL to 5 µL, with rapid plate-to-plate motion across three available deck positions and a small benchtop footprint[PL1] . Its use of individual pre-sterilized micropipettes eliminates the risk of cross-contamination, ensuring data and research integrity. Developed in collaboration with leading scientists, mosquito software enables quick method implementation and sharing, facilitating miniaturization in novel application areas.

For laboratories requiring higher throughput and greater walkaway capacity, mosquito HV genomics offers the same accuracy and volume range, with additional two deck positions.

mosquito technology has transformed genomics workflows by significantly reducing reagent consumption and scaling down reaction volumes without compromising data quality. Unlike traditional air displacement technology, mosquito’s true positive displacement technology maintains accuracy across all liquid classes and environmental conditions. This technology has enabled miniaturization of over 40 NGS kits, including industry standards such as Illumina Nextera XT, Illumina DNA Prep, NEBNext® Ultra™ II and Takara SMART-Seq chemistries. 

“Automated liquid handling has become essential for genomics labs to meet the demands of modern research. Miniaturization is a particularly advantageous technique that allows for substantial cost savings and maximum reach of precious samples and reagents. We’re lowering the cost barrier to miniaturization with mosquito Gen3, enabling more researchers to experience its benefits. Our expanded mosquito portfolio offers low-volume liquid handling solutions tailored to diverse laboratory resources and needs,” says Kamila Koprowska, Product Manager, mosquito genomics at SPT Labtech.

Contact

Carey Rooks, Head of Brand and Communications, SPT Labtech: marketing@sptlabtech.com

About SPT Labtech

SPT Labtech makes products that transform the way scientists work. For nearly two decades, our expert scientists, engineers, and business innovators have created innovative solutions for liquid handling, sample preparation and management that help accelerate research and make a real difference to human health. We work collaboratively with our customers, building trusted relationships that enable us to deliver exceptional, personalized experiences designed for real world challenges in the lab. For more information, please visit: www.sptlabtech.com

Follow SPT Labtech on Twitter @SPTLabtech and LinkedIn @SPT Labtech

Our latest News

discover more
New software helps researchers decode the cellular architecture of lymphoma

New software helps researchers decode the cellular architecture of lymphoma

An open-source analysis framework developed by researchers at EMBL, HHU, and other institutions makes it easier to study how cells are organised within tumours, paving the way for new insights into cancer biology Summary How cancer develops and responds to treatment depends not only on the tumour cells themselves but also on the complex ecosystem […]

EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

The spin-off aims to develop a new generation of precision medicines using epigenome editing to precisely regulate gene expression without altering DNA A newly launched EMBL spin-off, Epitome Therapeutics, aims to translate pioneering research in epigenome editing into a new generation of precision medicines. Co-founded by EMBL Group Leader Jamie Hackett, the company builds on cutting-edge […]

Complex Simulations: New Findings on Proton Transport in Water

Complex Simulations: New Findings on Proton Transport in Water

International research team simulates motions of a hydrated proton in full quantum detail Complex simulations – the most intricate of their kind to date – reveal how water governs the way protons move through it. They were carried out by an international research team led by scientists of Heidelberg University’s Institute for Physical Chemistry. Using […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp